title: Pfetin as a risk factor of recurrence in gastrointestinal stromal tumors.
abstract: Background. Despite complete resection of gastrointestinal stromal tumors (GIST), recurrent and/or metastatic disease occurs, often depending on the grade of malignancy. As such, markers are needed that accurately predict patients at high risk for recurrence. Previously our group reported Pfetin as a prognostic biomarker for GIST. In order to create an approach for predicting risk of recurrence, we incorporated Pfetin expression with clinicopathological data to produce a predictive model. Object. Forty-five patients with localized primary GIST were treated with complete gross surgical resection surgically at our institution between 1995 and 2010 were included. The majority of tumors originated in the stomach (38 cases), as well as small intestine (6 cases) and rectum (1 case). Method. (1) We performed retrospective analysis of the connection between Pfetin expression, clinicopathological data, and incidences of recurrence, using bivariate and multivariate analyses. (2) The reactivity of the monoclonal antibody against Pfetin was examined by immunohistochemistry. Pfetin. We have reported Pfetin, identified microarray technology, and compared between statistically different GISTs for good and poor prognoses and for prognostic marker. Results. There were 7 cases of recurrences. (1) By univariate analysis, tumor size, mitoses, exposure to abdominal cavity, and complete tumor removal predicted risk of recurrence. (2) Pfetin-negative cases were significantly related to recurrence (P = 0.002). Conclusions. This analysis demonstrates that lack of Pfetin expression is an additional predictor of recurrence in resected GIST. Further study may determine the role of this variable added to the current predictive model for selection of adjuvant therapy.
authors: Department of Surgery, Juntendo Shizuoka Hospital, Shizuoka, Japan.
authors: Hajime
authors: 0000-0002-8263-7069
authors: H
authors: Orita
authors: Department of Surgery, Juntendo Shizuoka Hospital, Shizuoka, Japan.
authors: Tomoaki
authors: 0000-0003-4190-8923
authors: T
authors: Ito
authors: Department of Surgery, Juntendo Shizuoka Hospital, Shizuoka, Japan.
authors: Tomoyuki
authors: 0000-0002-7987-8443
authors: T
authors: Kushida
authors: Department of Surgery, Juntendo Shizuoka Hospital, Shizuoka, Japan.
authors: Mutsumi
authors: M
authors: Sakurada
authors: Department of Surgery, Juntendo Shizuoka Hospital, Shizuoka, Japan.
authors: Hiroshi
authors: H
authors: Maekawa
authors: Department of Pathology, Juntendo Shizuoka Hospital, Shizuoka, Japan.
authors: Ryo
authors: R
authors: Wada
authors: Proteome Bioinformatics Project, National Cancer Center Research Institute, Japan.
authors: Yoshiyuki
authors: 0000-0001-8206-3037
authors: Y
authors: Suehara
authors: Proteome Bioinformatics Project, National Cancer Center Research Institute, Japan.
authors: Daisuke
authors: D
authors: Kubota
authors: Department of Surgery, Juntendo Shizuoka Hospital, Shizuoka, Japan.
authors: Koichi
authors: K
authors: Sato
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000601:surgery; D046152:Gastrointestinal Stromal Tumors / Q000175:diagnosis / Q000378:metabolism* / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000378:metabolism* / Q000517:prevention & control; D011379:Prognosis; D011506:Proteins / Q000378:metabolism*; D015203:Reproducibility of Results; D012307:Risk Factors; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; C493175:KCTD12 protein, human; D011506:Proteins